| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 149, 873-882, Copyright © 1996 by American Society for Investigative Pathology
REGULAR ARTICLES |
T Sugino, H Gorham, K Yoshida, J Bolodeoku, V Nargund, D Cranston, S Goodison and D Tarin
Nuffield Department of Pathology, University of Oxford, John Radcliffe Hospital, United Kingdom.
This study investigated CD44 gene expression at both the RNA and protein level in well differentiated superficial and in deeply invasive bladder carcinomas. Proteins were studied by immunohistochemistry using antibodies against standard (CD44s) and variant (CD44v) isoforms. mRNA was analyzed by reverse transcriptase polymerase chain reaction/Southern blotting and in situ hybridization. Immunostaining with antibodies against CD44s and CD44v2, -5 and -6 (exons 7, 10, and 11, respectively) showed that carcinoma cells in all papillary tumors expressed strong signals throughout the epithelium but especially in the basal layer, which abuts on the stroma. However, invasive tumors, which are believed to originate mainly from flat urothelial tumors or, less frequently, from papillary carcinomas, progressively lost CD44 proteins as they penetrated deeper and became less differentiated. This change was paralleled at the mRNA level, by the gradual loss of expression of CD44s and CD44v transcripts in deeply invasive tumors until they were virtually undetectable. Conversely, papillary tumors contained multiple higher molecular weight transcripts, suggesting that the loss of CD44 proteins in the more aggressive tumors is due to a disturbance in transcription. This concept was confirmed by in situ hybridization studies with a probe showing that substantial variant CD44 mRNA is located in the urothelium in papillary carcinomas but is absent from deeply invasive carcinomas. These results indicate that initially there is a striking increase in CD44 gene expression in early bladder carcinomas, relative to normal urothelium, but that this diminishes as the tumors acquire a more aggressive phenotype.
This article has been cited by other articles:
 |
|
 |
|
  S. M. Lee, K. E. Lee, H. J. Chang, M. Y. Choi, M.-S. Cho, S. K. Min, H. K. Lee, Y. C. Mun, E. M. Nam, C. M. Seong, et al. Prognostic Significance of CD44s Expression in Biliary Tract Cancers Ann. Surg. Oncol., April 1, 2008; 15(4): 1155 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. A. Rouschop, M. Sylva, G. J. D. Teske, I. Hoedemaeker, S. T. Pals, J. J. Weening, T. van der Poll, and S. Florquin Urothelial CD44 Facilitates Escherichia coli Infection of the Murine Urinary Tract J. Immunol., November 15, 2006; 177(10): 7225 - 7232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Guler, S. Sarac, A. Uner, E. Karabulut, A. Ayhan, and O. Hiroshi Prognostic Value of CD44 Variant 6 in Laryngeal Epidermoid Carcinomas Arch Otolaryngol Head Neck Surg, April 1, 2002; 128(4): 393 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Woodman, S. Goodison, M. Drake, J. Noble, and D. Tarin Noninvasive Diagnosis of Bladder Carcinoma by Enzyme-linked Immunosorbent Assay Detection of CD44 Isoforms in Exfoliated Urothelia Clin. Cancer Res., June 1, 2000; 6(6): 2381 - 2392. [Abstract] [Full Text]
|
|
|
|
 |
|
 V. Toma, D. Hauri, U. Schmid, D. Ackermann, R. Maurer, G. Alund, H. Knonagel, M. Rist, T. C. Gasser, G. Sauter, et al. Focal Loss of CD44 Variant Protein Expression is Related to Recurrence in Superficial Bladder Carcinoma Am. J. Pathol., November 1, 1999; 155(5): 1427 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Aogi, K. Kitahara, V. Urquidi, D. Tarin, and S. Goodison Comparison of Telomerase and CD44 Expression as Diagnostic Tumor Markers in Lesions of the Thyroid Clin. Cancer Res., October 1, 1999; 5(10): 2790 - 2797. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
